recombinant human N-acetylgalactosamine-6-sulfatase (Vivendy)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namerecombinant human N-acetylgalactosamine-6-sulfatase (Vivendy)

Drug Alias Nameenzyme replacement therapy (St Lousi University)enzyme replacement therapy (Vivendy)rhGALNS (St Louis University)rhGALNS (Vivendy)recombinant human N-acetylgalactosamine-6-sulfatase (St Louis University)

ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme

Mechanisms of ActionN-acetylgalactosamine-6-sulfatase stimulants

TargetsN-acetylgalactosamine-6-sulfatase

Therapy Area/IndicationsMucopolysaccharidosis IV

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesSaint Louis University

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesVivendy Therapeutics Ltd

Active IndicationsN/A

Inactive IndicationsMucopolysaccharidosis IV

Other Information

ATC CodeN/A